The Latest Breaking News from Amgen

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers preferring OpenAI's offering.

Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

A TSLA stock rebound led to gains surpassing the current market caps of Amgen or Adobe.

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

The announcement that 23andMe is filing for bankruptcy and has put its genetic genealogy database up for sale has sent its customers into a bit of a privacy tizzy. On March 21, California Attorney General Bob Bonta issued a consumer alert with detailed instructions about how to delete one’s data.